Since GLP-1 blockbusters semaglutide and tirzepatide broke into the mainstream for their ability to treat diabetes and provoke weight loss, evidence has been piling up that the molecules can reduce the risk of heart problems too. New data from rats and mice demonstrates that GLP-1s can support heart attack recovery by helping blood vessels relax—literally.


